Abstract:Context: Progress achieved in the treatment of prostate cancer (PCa) with surgical, radiation, and hormonal therapies has drastically reduced mortality from this disease. Yet, patients with advanced PCa have few, if any, curative options. Recent success in treating patients with hematological malignancies of B-cell origin using T cells engineered to express chimeric antigen receptors (CARs) has inspired multiple groups worldwide to adapt this approach to the problem of late-stage PCa. Objective: To summarize the available clinical results for CAR T-cell therapy of PCa and discuss future technological advancements in the CAR T-cell field that may help patients with metastatic PCa. Evidence acquisition: A literature review was conducted of clinical trial data, abstracts presented at recent oncology conferences, as well as reports highlighting critical bottlenecks of CAR T-cell therapy that became apparent from preclinical and clinical studies. Evidence synthesis: Current understanding of why CAR T-cell therapy may fail, particularly in the context of solid cancers, is as follows. First, a CAR design that provides potent activity and persistence of engineered T cells in the hostile tumor microenvironment is a must. The choice of the targetable epitope(s) is critical to counteract tumor antigen escape. Preclinical and clinical evidence indicates that the efficacy of CAR T-cell therapy can be enhanced significantly in combination with other therapeutic approaches. We propose that several improvements to CAR design and patient conditioning, such as unbiased identification of novel PCa-specific CAR targets, use of next-generation (multispecific, resistant to the tumor microenvironment, and with prolonged persistence) CAR T-cell products, and combination therapies may translate into improved patient outcomes and more durable responses. Conclusions: Although significant preclinical experience of testing CAR T cells in solid cancer models has identified important technological and biological bottlenecks, information from clinical trials, particularly those focusing on the PCa, will be instrumental to the rational design of advanced CAR T therapies that will be both safe and effective in patients with advanced PCa. Patient summary: So far, chimeric antigen receptor (CAR) T-cell therapy has not shown significant activity in patients with metastatic prostate cancer (PCa). CAR T-cell products used for such trials represent one of the pioneering efforts to adapt this technology to the problem of metastatic PCa. In retrospect, both CAR design and cell composition appear to have been suboptimal to expect strong patient responses. Given the impressive results of CAR-based approaches observed in preclinical models of solid cancers, emerging CAR T-cell products are expected to be more successful in the clinic. Here, we discuss the challenges that need to be overcome to boost the efficacy of PCa-targeted CAR T-cell therapy and call for dialogue between clinicians and cell biologists to address these challenges.

Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Current state of theranostics in metastatic castrate‐resistant prostate cancer

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches

Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

How We Treat Metastatic Castration-Sensitive Prostate Cancer

Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy

Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer

Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others

Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer

The Current Therapeutic Landscape for Metastatic Prostate Cancer

Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease

Advances in PSMA-targeted therapy for prostate cancer

New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy